These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37229040)

  • 1. Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal.
    Sharma S; Kharel R; Parajuli S; Jha S
    Ann Med Surg (Lond); 2023 May; 85(5):1486-1489. PubMed ID: 37229040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
    Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India.
    Sadhu S; Dutta Majumder P; Biswas J
    Indian J Ophthalmol; 2020 Sep; 68(9):1929-1933. PubMed ID: 32823417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.
    Pasadhika S; Rosenbaum JT
    Biologics; 2014; 8():67-81. PubMed ID: 24600203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics in the Treatment of Uveitis.
    Dingerkus VLS; Becker MD; Doycheva D
    Klin Monbl Augenheilkd; 2022 May; 239(5):686-694. PubMed ID: 35426112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics in ocular inflammatory diseases - Experience from a tertiary referral eye care center in South India.
    Babu K; Padmapriya PG; Rao AP; Jois R
    Indian J Ophthalmol; 2024 Sep; ():. PubMed ID: 39257099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric Uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment.
    Yiu MK; Ho M; Ho ACH; Chan WKY; Yung W; Yip WWK; Young AL
    J Ophthalmic Inflamm Infect; 2024 Jul; 14(1):34. PubMed ID: 39017721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninfectious Uveitis in Rheumatology: Patterns, Treatment, and Outcomes.
    Younus R; Saeed MA; Arshad M; Farman S; Ahmad NM
    Cureus; 2023 Jun; 15(6):e39965. PubMed ID: 37416043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis.
    Park SE; Jun JW; Lee DH; Lee SC; Kim M
    Yonsei Med J; 2021 Feb; 62(2):177-181. PubMed ID: 33527798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
    Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
    Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 13. [Biologics in uveitis].
    Feurer E; Bielefeld P; Saadoun D; Sève P
    Rev Med Interne; 2015 Feb; 36(2):107-16. PubMed ID: 25239400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India.
    Khan N; Dutta Majumder P; Janarthanan M; Biswas J
    Indian J Ophthalmol; 2024 Dec; 72(12):1766-1771. PubMed ID: 38990630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
    Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
    Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
    Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
    Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib for Refractory Uveitis and Scleritis in Children: A Case Series.
    Dutta Majumder P; Abraham S; Sudharshan S; Janarthanan M; Ramanan AV
    Ocul Immunol Inflamm; 2024 Nov; 32(9):2092-2095. PubMed ID: 38441607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: A Promising Treatment Strategy for Noninfectious Uveitis.
    Liu XB; Tang LS; Chen JW; Lin CS; Liu QH; Xu Q
    Front Pharmacol; 2021; 12():784860. PubMed ID: 35115933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.